CN102427809B - 用于治疗代谢性疾病的抗炎剂和抗氧化剂轭合物 - Google Patents

用于治疗代谢性疾病的抗炎剂和抗氧化剂轭合物 Download PDF

Info

Publication number
CN102427809B
CN102427809B CN201080021409.1A CN201080021409A CN102427809B CN 102427809 B CN102427809 B CN 102427809B CN 201080021409 A CN201080021409 A CN 201080021409A CN 102427809 B CN102427809 B CN 102427809B
Authority
CN
China
Prior art keywords
formula
hydrogen
alkyl
patient
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080021409.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN102427809A (zh
Inventor
A.米安
L.马蒂克劳泽尔
E.梅尤克斯
S.加西亚文森特
M.塞拉诺穆尼奥斯
A.佐扎诺奥拉特
J.塞萨卡斯特罗帕洛米诺拉里亚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genmedica Therapeutics SL
Original Assignee
Genmedica Therapeutics SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genmedica Therapeutics SL filed Critical Genmedica Therapeutics SL
Publication of CN102427809A publication Critical patent/CN102427809A/zh
Application granted granted Critical
Publication of CN102427809B publication Critical patent/CN102427809B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/02—Five-membered rings
    • C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/13—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C07C309/14—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton
    • C07C309/15—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton the nitrogen atom of at least one of the amino groups being part of any of the groups, X being a hetero atom, Y being any atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/20—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/20—Esters of monothiocarboxylic acids
    • C07C327/32—Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C07C327/34—Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups with amino groups bound to the same hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C329/00—Thiocarbonic acids; Halides, esters or anhydrides thereof
    • C07C329/02—Monothiocarbonic acids; Derivatives thereof
    • C07C329/04—Esters of monothiocarbonic acids
    • C07C329/06—Esters of monothiocarbonic acids having sulfur atoms of thiocarbonic groups bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201080021409.1A 2009-03-16 2010-03-16 用于治疗代谢性疾病的抗炎剂和抗氧化剂轭合物 Expired - Fee Related CN102427809B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US16064209P 2009-03-16 2009-03-16
US61/160,642 2009-03-16
US17795809P 2009-05-13 2009-05-13
US61/177,958 2009-05-13
US22762009P 2009-07-22 2009-07-22
US61/227,620 2009-07-22
PCT/EP2010/053418 WO2010106082A1 (en) 2009-03-16 2010-03-16 Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders

Publications (2)

Publication Number Publication Date
CN102427809A CN102427809A (zh) 2012-04-25
CN102427809B true CN102427809B (zh) 2014-10-01

Family

ID=42111633

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080021409.1A Expired - Fee Related CN102427809B (zh) 2009-03-16 2010-03-16 用于治疗代谢性疾病的抗炎剂和抗氧化剂轭合物

Country Status (8)

Country Link
US (2) US8575217B2 (enExample)
EP (1) EP2408443A1 (enExample)
JP (1) JP2012520342A (enExample)
CN (1) CN102427809B (enExample)
AU (1) AU2010224866C1 (enExample)
BR (1) BRPI1013878A2 (enExample)
CA (1) CA2755069A1 (enExample)
WO (1) WO2010106082A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5519645B2 (ja) 2008-05-20 2014-06-11 ニューロジェシックス， インコーポレイテッド カーボネートプロドラッグおよびそれを使用する方法
MX2010012648A (es) 2008-05-20 2010-12-14 Neurogesx Inc Analogos de acetaminofeno solubles en agua.
US8466197B2 (en) 2010-12-14 2013-06-18 Genmedica Therapeutics Sl Thiocarbonates as anti-inflammatory and antioxidant compounds useful for treating metabolic disorders
CA2821807A1 (en) * 2010-12-21 2012-06-28 Nestec S.A. Methods and compositions suitable for managing blood glucose in animals
MX343409B (es) 2011-09-16 2016-11-04 Genmedica Therapeutics S L Combinaciones farmaceuticas que incluyen conjugados antiinflamatorios y antioxidantes utiles para tratar trastornos metabolicos.
WO2013037984A1 (en) 2011-09-16 2013-03-21 Genmedica Therapeutics Sl Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders
US9024055B2 (en) * 2011-09-22 2015-05-05 Acorda Therapeutics, Inc. Acetaminophen conjugates, compositions and methods of use thereof
WO2013168011A1 (en) * 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of chronic pain
CA3078006C (en) * 2012-07-10 2022-04-26 Xpd Holdings, Llc Stabilized multi-functional antioxidant compounds and methods of use
US20150209442A1 (en) * 2012-08-31 2015-07-30 The Board Of Regents Of The University Of Texas System Method to improve pharmacokinetics of drugs
US9029342B2 (en) 2012-09-17 2015-05-12 Board Of Regents Of The University Of Texas System Compositions of matter that reduce pain, shock, and inflammation by blocking linoleic acid metabolites and uses thereof
EP2716574B1 (en) 2012-10-02 2015-12-16 Reemtsma Cigarettenfabriken GmbH Package for tobacco related articles and method of manufacturing the package
WO2015037659A1 (ja) 2013-09-13 2015-03-19 株式会社医薬分子設計研究所 水溶液製剤及びその製造方法
LT3066089T (lt) 2013-11-08 2020-02-25 Promentis Pharmaceuticals, Inc. Pakeistieji n-acetil-l-cisteino dariniai ir giminingi junginiai
EP3102557B1 (en) 2014-02-06 2020-01-29 Biocogent, LLC Improved compositions and methods comprising resveratrol
WO2016040342A1 (en) * 2014-09-08 2016-03-17 Kansas State University Research Foundation Early lactation administration of non-steroidal anti-inflammatory drugs to increase whole-lactation milk yield
WO2017015013A1 (en) * 2015-07-17 2017-01-26 The Board Of Regents Of The University Of Oklahoma Licofelone derivatives and methods of use
KR101601685B1 (ko) * 2015-08-24 2016-03-09 여명바이오켐 주식회사 항산화 효과가 우수한 택시폴린 유도체 및 이를 함유하는 화장료 조성물
WO2018174839A1 (en) * 2017-03-18 2018-09-27 Nguyen Mark Quang Cysteine, n-acetylcysteine and penicillamine prodrugs, pharmaceutical compositions thereof, and methods of use
WO2018170765A1 (zh) * 2017-03-22 2018-09-27 深圳市博奥康生物科技有限公司 Imd16基因的rna干涉载体及其应用
KR102048982B1 (ko) * 2017-11-10 2019-11-26 원광대학교 산학협력단 이데베논 유도체 화합물 및 이를 포함하는 화장료 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006066894A1 (en) * 2004-12-24 2006-06-29 Ctg Pharma S.R.L. Compounds for treating metabolic syndrome
WO2007127913A2 (en) * 2006-04-28 2007-11-08 Joslin Diabetes Center, Inc. Reducing risk of type 2 diabetes (t2d)

Family Cites Families (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1583602A (en) 1977-05-26 1981-01-28 Sterwin Ag N-acetyl-para-aminophenyl-n'-acetyl-amino-thioalkanoic acid ester derivatives
IT1134458B (it) 1980-11-26 1986-08-13 Real Sas Di Alberto Reiner Derivato della n-acetil-cisteina ad attivita' terapeutica,procedimento per la sua preparazione e relative composizioni farmaceutiche
IT1194117B (it) 1981-11-20 1988-09-14 Isnardi Pietro & C Spa Derivati salicilici di n-acetilcisteina
IT1190987B (it) 1982-09-07 1988-02-24 Pharma Edmond Srl Tioesteri dell'acido acetilsalicilico,procedimento per la loro preparazione e composizioni farmaceutiche che li conttengono
IT1206515B (it) 1983-08-09 1989-04-27 Guidotti & C Spa Labor N-acetilcisteina ederivati 2',4's-carbossimetilcisteina ad-difluoro-4-idrossi-(1,1'-bifenil)attivita' antinfiammatoria, 3-carbossilici della mucolitica, procedimento per laloro preparazione e relative composizioni farmaceutiche.
US5656620A (en) 1984-01-28 1997-08-12 Ismail; Roshdy Method for treating pain
ES8609231A1 (es) 1985-12-03 1986-09-01 Farmhispania Procedimiento de obtencion del n-acetil-3(2-(acetiloxi)ben- zoilmercapto)alanina
ES8800144A1 (es) 1986-05-09 1987-11-01 Lasa Lab Procedimiento de obtencion de un tioester de la n-acetilcisteina y de sus sales de interes terapeutico
EP0254032A3 (en) 1986-06-20 1990-09-05 Schering Corporation Neutral metalloendopeptidase inhibitors in the treatment of hypertension
IT1213301B (it) 1986-07-14 1989-12-20 Zambon Spa Composizioni per il trattamento del le sindromi da ischemia e riperfusione
IT1228537B (it) 1987-07-30 1991-06-20 Magis Farmaceutici Derivati della cisteina ad azione espettorante
US5610180A (en) 1988-01-29 1997-03-11 Virginia Commonwealth University Ionizable congeners of aromatic and aliphatic alcohols as anti-leukemia agents
US8178516B2 (en) 1992-06-30 2012-05-15 Sylvan Labs, LLC Compositions and method for treatment of chronic inflammatory diseases
DE4327462A1 (de) 1993-08-16 1995-02-23 Carl Heinrich Dr Weischer Neue N-Acetyl-p-Aminophenol-Derivate zur Bekämpfung von Schmerzzuständen
RU2054936C1 (ru) 1994-04-07 1996-02-27 Елизарова Евгения Павловна Мембраностабилизирующее средство для лечения больных с инсулинзависимым и инсулиннезависимым сахарным диабетом
DE4444051A1 (de) 1994-12-10 1996-06-13 Rhone Poulenc Rorer Gmbh Pharmazeutische, oral anwendbare Zubereitung
US5871769A (en) 1996-01-18 1999-02-16 Fleming & Company, Pharmaceuticals Methods and compositions for the prevention and treatment of diabetes mellitus
CN1230178A (zh) 1996-09-10 1999-09-29 麦地诺克斯公司 含聚二硫代氨基甲酸酯的大分子和其用于治疗和诊断应用的用途
US6896899B2 (en) 1996-12-31 2005-05-24 Antioxidant Pharmaceuticals Corp. Pharmaceutical preparations of glutathione and methods of administration thereof
IL123887A0 (en) 1997-04-02 1998-10-30 Sankyo Co Dithiolan derivatives their use and pharmaceutical compositions containing the same
AUPO612397A0 (en) 1997-04-11 1997-05-08 University Of Queensland, The Novel diflunisal esters and related compounds
EA010183B1 (ru) 1997-05-14 2008-06-30 Атеродженикс, Инк. Сложный моноэфир янтарной кислоты и пробукола для лечения сердечно-сосудистых и воспалительных заболеваний
US6852878B2 (en) 1998-05-14 2005-02-08 Atherogenics, Inc. Thioketals and thioethers for inhibiting the expression of VCAM-1
US20020004515A1 (en) 1997-06-18 2002-01-10 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and metformin
US5972986A (en) 1997-10-14 1999-10-26 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
US6197340B1 (en) 1998-05-28 2001-03-06 Medical Research Institute Controlled release lipoic acid
AU4543899A (en) 1998-06-08 1999-12-30 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
US20020045580A1 (en) 1999-11-24 2002-04-18 Sacks Meir S. Compositions for raising uric acid levels and methods of using same
CA2339218C (en) 1998-07-31 2008-10-28 Mount Sinai Hospital Methods and compositions for increasing insulin sensitivity
CA2344246A1 (en) 1998-09-17 2000-03-23 Akesis Pharmaceuticals, Inc. Combinations of chromium or vanadium with antidiabetics for glucose metabolism disorders
US6201028B1 (en) 1998-12-08 2001-03-13 The Rockefeller University Methods and compositions for prevention and treatment of atherosclerosis and hyperlipidemia with non-steroidal anti-inflammatory drugs
IT1311924B1 (it) 1999-04-13 2002-03-20 Nicox Sa Composti farmaceutici.
US20010051184A1 (en) 1999-05-20 2001-12-13 Madalene C.Y. Heng Method for using soluble curcumin to inhibit phosphorylase kinase in inflammatory diseases
JP4618845B2 (ja) 1999-06-09 2011-01-26 杏林製薬株式会社 ヒトペルオキシゾーム増殖薬活性化受容体（ＰＰＡＲ）αアゴニストとしての置換フェニルプロピオン酸誘導体
CA2377414A1 (en) 1999-06-15 2000-12-21 John D. Potter Nutrient formulations for disease reduction, and related treatment and component screening methods
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
AU7995300A (en) 1999-10-05 2001-05-10 Bethesda Pharmaceuticals, Inc. Dithiolane derivatives
US7323496B2 (en) * 1999-11-08 2008-01-29 Theracos, Inc. Compounds for treatment of inflammation, diabetes and related disorders
US20020155163A1 (en) 1999-12-27 2002-10-24 Samuel D. Benjamin Integrated multi-vitamin and mineral combination
US20080044399A1 (en) 2000-04-20 2008-02-21 Andrew Levy Vitamin E supplementation for reducing cardiovascular events in individuals with DM and the Hp 2-2 genotype
US20080213785A1 (en) 2000-04-20 2008-09-04 Andrew Levy Method of predicting a benefit of antioxidant therapy for prevention or treatment of vasclar disease in hyperglycemic individuals
US20020037855A1 (en) 2000-05-05 2002-03-28 Fritz Stanislaus Stabilized medicament containing cysteinyl derivatives
US6355666B1 (en) 2000-06-23 2002-03-12 Medinox, Inc. Protected forms of pharmacologically active agents and uses therefor
US6429223B1 (en) 2000-06-23 2002-08-06 Medinox, Inc. Modified forms of pharmacologically active agents and uses therefor
US6365176B1 (en) 2000-08-08 2002-04-02 Functional Foods, Inc. Nutritional supplement for patients with type 2 diabetes mellitus for lipodystrophy
IT1319201B1 (it) 2000-10-12 2003-09-26 Nicox Sa Farmaci per il diabete.
US20020098247A1 (en) 2000-11-02 2002-07-25 Komorowski James R. Methods and compositions for the improvement of insulin sensitivity, reduction of hyperglycemia, and reduction of hypercholesterolemia with chromium complexes and alpha lipoic acid
US6589948B1 (en) 2000-11-28 2003-07-08 Eukarion, Inc. Cyclic salen-metal compounds: reactive oxygen species scavengers useful as antioxidants in the treatment and prevention of diseases
AU2002230848B2 (en) 2000-12-14 2008-01-24 The Brigham And Women's Hospital, Inc. Inflammatory markers for detection and prevention of diabetes mellitus
DE50104197D1 (de) 2000-12-28 2004-11-25 Fresenius Kabi Austria Gmbh Gr Stabile Infusionslösung von Diclofenac-Salzen, deren Herstellung und Verwendung
US20030191064A1 (en) 2001-01-23 2003-10-09 Kopke Richard D. Methods for preventing and treating loss of balance function due to oxidative stress
JP2002226457A (ja) 2001-02-02 2002-08-14 Ajinomoto Co Inc 新規シスチン誘導体及び炎症因子活性化抑制剤
US6566401B2 (en) 2001-03-30 2003-05-20 The Board Of Trustees Of The Leland Stanford Junior University N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
RS51031B (sr) 2001-04-30 2010-10-31 Trommsdorff Gmbh & Co.Kg.Arzneimittel Farmaceutski aktivni estri uridina
US6669955B2 (en) 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US20050019399A1 (en) 2001-09-21 2005-01-27 Gina Fischer Controlled release solid dispersions
FR2835433B1 (fr) 2002-02-01 2006-02-17 Richard Lab M Utilisation de la 1-(-4-chlorobenzoyl)-5methoxy-2-methyl-1h- indole-3acetic 4-(acetylamino)phenylester pour la fabrication d'un medicament destine a inhiber exclusivement la cox2
MXPA04008195A (es) * 2002-03-14 2004-11-26 Bayer Pharmaceuticals Corp Metodos para el tratamiento de la diabetes empleando inhibidores de pde11a.
US7670612B2 (en) 2002-04-10 2010-03-02 Innercap Technologies, Inc. Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
AU2003253887A1 (en) 2002-07-12 2004-02-02 Atherogenics, Inc. Novel salt forms of poorly soluble probucol esters and ethers
US7148211B2 (en) 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
CA2504329C (en) 2002-11-01 2013-08-20 Biodelivery Sciences International, Inc. Geodate delivery vehicles
US8017651B2 (en) 2002-11-22 2011-09-13 Bionexus, Ltd. Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia
CN1233629C (zh) 2002-11-22 2005-12-28 贵州省中国科学院天然产物化学重点实验室 具有神经营养作用的硫酯类化合物及其它的合成方法和应用
US8093292B2 (en) 2002-11-22 2012-01-10 Bionexus, Ltd. Methods for the treatment of HIV-1 related fat maldistribution, fasting hyperlipidemia and modification of adipocyte physiology
MXPA02012315A (es) 2002-12-13 2004-06-24 Univ Autonoma Metropolitana Compuesto farmaceutico que contiene silimarina y carbopol, su proceso de fabricacion y su uso como regenerador del tejido y celulas pancreaticas de secrecion endogena danados por diabetes mellitus.
US20090036516A1 (en) 2003-01-13 2009-02-05 Ctg Pharma S.R.L. Compounds for treating metabolic syndrome
WO2004082621A2 (en) 2003-03-15 2004-09-30 Bethesda Pharmaceuticals, Inc. Novel ppar agonists, pharmaceutical compositions and uses thereof
US7981915B2 (en) 2003-04-30 2011-07-19 Beth Israel Deaconess Medical Center Methods for modulating PPAR biological activity for the treatment of diseases caused by mutations in the CFTR gene
AT500404A1 (de) 2003-07-17 2005-12-15 Jsw Res Forschungslabor Gmbh Chemische verbindungen enthaltend tocopherol sowie zumindest einen weiteren pharmazeutischen wirkstoff
US8173840B2 (en) 2003-07-29 2012-05-08 Signature R&D Holdings, Llc Compounds with high therapeutic index
WO2005032505A1 (de) 2003-09-22 2005-04-14 Juvena (International) Ag Haut- und haarpflegezubereitung enthaltend eine kombination aus proteinhydrolysaten
US20070254055A1 (en) 2003-11-21 2007-11-01 Trustees Of Tufts College Therapeutic Avenanthramide Compounds
US7078064B2 (en) 2003-12-03 2006-07-18 George Zabrecky Compositions and methods useful for treating and preventing chronic liver disease, chronic HCV infection and non-alcoholic steatohepatitis
US20050143356A1 (en) 2003-12-08 2005-06-30 Vanderbilt University Selective inhibition of cyclooxygenase 1 in the treatment of diabetic nephropathy
US20050171027A1 (en) 2003-12-29 2005-08-04 President And Fellows Of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
WO2005092387A1 (en) 2004-03-10 2005-10-06 Shimoda Biotech (Pty) Ltd Stable injectable diclofenac compositions
EP2266586A1 (en) 2004-03-23 2010-12-29 Lifeline Nutraceuticals Corporation Compositions and method for alleviating inflammation and oxidative stress in a mammal
WO2005112914A2 (en) 2004-04-20 2005-12-01 Atherogenics, Inc. Phenolic antioxidants for the treatment of disorders including arthritis, asthma and coronary artery disease
CA2566861A1 (en) 2004-05-17 2005-12-08 Combinatorx, Incorporated Methods and reagents for the treatment of immunoinflammatory disorders
JP4218601B2 (ja) 2004-06-29 2009-02-04 トヨタ自動車株式会社 圧縮着火内燃機関の空燃比センサ劣化判定システム
AU2005259864A1 (en) * 2004-06-30 2006-01-12 Combinatorx, Incorporated Methods and reagents for the treatment of metabolic disorders
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
US20080038316A1 (en) 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
US20070248705A1 (en) 2004-10-22 2007-10-25 Kirin Beer Kabushiki Kaisha Agents for Activating the Transcription Factor Nrf2 and Foods Having Such Function
US20060099279A1 (en) 2004-11-09 2006-05-11 Council Of Scientific & Industrial Research Novel anti-diabetic herbal formulation
SG144145A1 (en) 2004-12-08 2008-07-29 Sirion Therapeutics Inc Methods, assays and compositions for treating retinol-related diseases
US20060166901A1 (en) 2005-01-03 2006-07-27 Yu Ruey J Compositions comprising O-acetylsalicyl derivatives of aminocarbohydrates and amino acids
WO2006079021A2 (en) 2005-01-20 2006-07-27 Sirtris Pharmaceuticals, Inc. Use of sirtuin-activating compounds for treating flushing and drug induced weight gain
CA2595469A1 (en) * 2005-01-21 2006-07-27 Pu Xia A method of treating cellular damage
US20060172012A1 (en) 2005-01-28 2006-08-03 Finley John W Anti-inflammatory supplement compositions and regimens to reduce cardiovascular disease risks
US20080033027A1 (en) 2005-03-21 2008-02-07 Vicus Therapeutics Spe 1, Llc Drug combination pharmaceutical compositions and methods for using them
EP1865779A4 (en) 2005-03-21 2008-06-04 Vicus Therapeutics Spe 1 Llc COMPOSITIONS AND METHODS FOR ENHANCING CACHEXIA
KR20080028357A (ko) 2005-04-21 2008-03-31 글렌 에이. 골드스타인 산화성 스트레스에 관련된 질병 및 증상 치료용ｎ-아세틸시스테인 아미드(ｎａｃ 아미드)
US20060270635A1 (en) * 2005-05-27 2006-11-30 Wallace John L Derivatives of 4- or 5-aminosalicylic acid
US20070149466A1 (en) 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
US20090325975A1 (en) 2005-07-15 2009-12-31 Helmut H Buschmann Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain
AU2006278504B2 (en) 2005-08-04 2013-01-17 Sirtris Pharmaceuticals, Inc. Imidazopyridine derivatives as sirtuin modulating agents
US7666898B2 (en) 2005-11-03 2010-02-23 Ilypsa, Inc. Multivalent indole compounds and use thereof as phospholipase-A2 inhibitors
DE102005057178A1 (de) 2005-11-30 2007-07-19 Basf Ag Verwendung von Zinksalzen der Liponsäure zur Behandlung von Fettstoffwechselstörungen
EP1957109A2 (en) 2005-12-02 2008-08-20 Sirtris Pharmaceuticals, Inc. Modulators of cdc2-like kinases (clks) and methods of use thereof
WO2007067570A1 (en) 2005-12-05 2007-06-14 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of disease
US20070231273A1 (en) 2006-03-31 2007-10-04 Jie Wu Method for Decreasing Blood Glucose Levels
US20080015251A1 (en) 2006-04-10 2008-01-17 Yissum Research Development Co., Of The Hebrew University Of Jerusalem Means and method for treating lipotoxicity and other metabolically related phenomena
WO2007117048A1 (en) 2006-04-10 2007-10-18 Seoul National University Industry Foundation Inhibitors against g6pd enzyme for treating and preventing oxidative stress and/or inflammatory related diseases and method for screening the same
EP2610242A1 (en) * 2006-07-09 2013-07-03 Techfields Biochem Co. Ltd Positively charged water-soluble prodrugs of aspirin
CN101489985B (zh) * 2006-07-18 2014-01-08 天津昕晨泰飞尔医药科技有限公司 具有快速皮肤穿透率的带正电荷的水溶性布洛芬前药
PL2046727T3 (pl) * 2006-07-25 2014-08-29 Techfields Biochem Co Ltd Dodatnio naładowane rozpuszczalne w wodzie proleki diklofenaku o bardzo szybkim stopniu przenikania przez skórę
CN101500983B (zh) * 2006-07-26 2015-09-16 于崇曦 具有快速皮肤穿透速度的带正电荷的水溶性二氟尼柳及相关化合物的前药
WO2008027547A2 (en) 2006-08-31 2008-03-06 The Brigham And Women's Hospital, Inc. Antioxidant therapies
EP2061749B1 (en) * 2006-09-03 2018-02-21 Techfields Biochem Co. Ltd Positively charged water-soluble prodrugs of acetaminophen and related compounds with very fast skin penetration rate
CA2664844A1 (en) 2006-10-06 2008-10-23 Celtaxsys, Inc. Chemorepulsion of cells
US7498048B2 (en) 2006-11-16 2009-03-03 Jose Angel Olalde Rangel Renal phyto-nutraceutical composition
BRPI0806774A2 (pt) 2007-01-16 2011-09-13 Ipintl Llc composição para tratamento de sìndrome metabólica
ES2352880T3 (es) * 2007-03-08 2011-02-23 Irm Llc Compuestos y composiciones como moduladores de la actividad de gpr119.
WO2009085695A1 (en) 2007-12-31 2009-07-09 Horwitz Lawrence D Treatment or prevention of skin injury due to exposure to ultraviolet light
WO2009089011A2 (en) 2008-01-08 2009-07-16 Sirtris Pharmaceuticals, Inc. Resveratrol formulations
CN102316730A (zh) * 2008-05-09 2012-01-11 天雅瑞药业有限公司 用于减轻全身性炎症和/或血管炎症的n-乙酰半胱氨酸(nac)的控释
CN102088965B (zh) 2008-05-13 2013-05-08 根梅迪卡治疗公司 水杨酸盐(酯)缀合物在制备用于治疗代谢性病症的药物中的应用
CN102421424A (zh) 2009-03-16 2012-04-18 根梅迪卡治疗公司 用于治疗代谢性疾病的组合疗法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006066894A1 (en) * 2004-12-24 2006-06-29 Ctg Pharma S.R.L. Compounds for treating metabolic syndrome
WO2007127913A2 (en) * 2006-04-28 2007-11-08 Joslin Diabetes Center, Inc. Reducing risk of type 2 diabetes (t2d)

Also Published As

Publication number Publication date
US8575217B2 (en) 2013-11-05
US20100234452A1 (en) 2010-09-16
US20130281520A1 (en) 2013-10-24
WO2010106082A1 (en) 2010-09-23
BRPI1013878A2 (pt) 2016-04-05
AU2010224866A1 (en) 2011-10-06
JP2012520342A (ja) 2012-09-06
AU2010224866C1 (en) 2015-01-15
CN102427809A (zh) 2012-04-25
AU2010224866B2 (en) 2014-03-06
EP2408443A1 (en) 2012-01-25
CA2755069A1 (en) 2010-09-23

Similar Documents

Publication Publication Date Title
CN102427809B (zh) 用于治疗代谢性疾病的抗炎剂和抗氧化剂轭合物
CN102088965B (zh) 水杨酸盐(酯)缀合物在制备用于治疗代谢性病症的药物中的应用
AU2002342968B2 (en) Fatty acid compounds, preparation and uses thereof
JP4637304B2 (ja) 芳香族及び複素環の硝酸誘導体
TW200526567A (en) Prostaglandin derivatives
CA2897571A1 (en) Nitric oxide releasing prodrugs of therapeutic agents containing at least one carboxylic acid group
US5686450A (en) Use of N,N'-bis(mercaptoacetyl) hydrazine derivatives as anticataract agents
CA2627211C (fr) Derives d'amino-acides contenant un groupement disulfanyle comme inhibiteurs mixtes de la neprilysine et de l'aminopeptidase n
CN103945839B (zh) 用于治疗代谢障碍的含抗炎剂和抗氧化剂缀合物的药物组合
US8466197B2 (en) Thiocarbonates as anti-inflammatory and antioxidant compounds useful for treating metabolic disorders
AU2013257708A1 (en) Compositions and methods for the treatment of diabetes
EP1940818A1 (fr) Derives d'amino-acides contenant un groupement disulfanyle comme inhibiteurs mixtes de la neprilysine et de l 'aminopeptidase n
WO2013037984A1 (en) Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders
CN116731307A (zh) 一种大环内酯聚合物及其制备方法与抑制促炎细胞因子作用的应用
CN114957148A (zh) 富马酸衍生物及其制备方法和医药用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20141001

Termination date: 20180316

CF01 Termination of patent right due to non-payment of annual fee